Collateral tumor damage

Australian researchers are taking a new approach to attacking brain cancer-raising T cells against antigens from the cytomegalovirus frequently found in gliomas rather than against tumor targets.¹ The approach has shown efficacy in patients, and the next steps include applying the method to larger cohorts and identifying the best cytomegalovirus epitopes to be used to activate T cells.

Glioblastoma multiforme (GBM) is an aggressive malignancy, with median survival of less than 15 months and a 5-year survival rate below 10%.^2,3Standard care includes surgical resection, radiotherapy and chemotherapy...